Posted On: 03/15/2015 8:35:55 PM
Post# of 1086
Re: chartguy89 #893
Great Charting.. Did anyone else see this..
In November 2013 the FDA gave Nuvilex Inc. and its subsidiary Medical Marijuana Sciences, sponsors of the University of London study, permission to begin clinical trials of CBD. The approval appears to signify a shift in the level of support given to cannabis research by federal regulators.
According to the FDA, among the 60-some known cannabinoids found in cannabis, CBD is the second most abundant (after THC) and offers therapeutic benefits without the "high" which can be psychologically disturbing for some individuals or lead to addictions in others.
As more states approve the use of “medical marijuana” for pain management and regulators express interest in the potential therapeutic benefit of cannabis in disease management, it's likely that cannabis research will also grow exponentially, and lead to a greater number of cannabis-based medicines reaching the marketplace over the next decade.
In November 2013 the FDA gave Nuvilex Inc. and its subsidiary Medical Marijuana Sciences, sponsors of the University of London study, permission to begin clinical trials of CBD. The approval appears to signify a shift in the level of support given to cannabis research by federal regulators.
According to the FDA, among the 60-some known cannabinoids found in cannabis, CBD is the second most abundant (after THC) and offers therapeutic benefits without the "high" which can be psychologically disturbing for some individuals or lead to addictions in others.
As more states approve the use of “medical marijuana” for pain management and regulators express interest in the potential therapeutic benefit of cannabis in disease management, it's likely that cannabis research will also grow exponentially, and lead to a greater number of cannabis-based medicines reaching the marketplace over the next decade.
(0)
(0)
